H.C. Wainwright lowered the firm’s price target on Mainz Biomed to $5 from $9 and keeps a Buy rating on the shares post the Q3 report
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
- Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Mainz Biomed reports Q3 EPS (39c), consensus (47c)
- Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
- Mainz Biomed to sell 4.17M shares at $1.20 in registered direct offering